MedTrace Logo

Fascia Iliaca Block for Postoperative Pain Control After Elective Hip Arthroplasty

NCT06534697 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2024-08-02

No results posted yet for this study

Summary

This clinical trial aims to assess the analgesic efficacy of ultrasound-guided FIB using different analgesic combinations administered into the iliac fascia compartment. The main question it aims to answer is:

·What is the total morphine (mg) consumption at 24 hours postoperatively for each of the three groups?

The secondary questions are:

* What is the length of stay in hospital for each group?
* What is the risk of falling associated with the use of fascia iliaca block? Researchers will compare two analgesic combinations of local anesthestic naropin 0,25% versus dextrose 10% administered by fascia iliaca block for postoperative pain after total hip arthroplasty.

Conditions

  • Hip Osteoarthritis

Interventions

DRUG

Naropin, 0.2% Injectable Solution in Sodium chloride

Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride

DRUG

Naropin, 0.2% Injectable Solution in dextrose 5%

Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%

DRUG

Dextrose 10 % in Water

Preoperative fascia iliaca block with 40 ml volume of dextrose 10%

Sponsors & Collaborators

  • Foisor Orthopedics Clinical Hospital

    lead OTHER

Principal Investigators

  • Denisa Anastase, MD, PhD · Foisor OCH

  • Simona Anastase, MD, PhD · Foisor OCH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-22
Primary Completion
2024-12-30
Completion
2025-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06534697 on ClinicalTrials.gov